Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Key Highlights
- ➤ACR-2316 Phase 1 study data will feature in a late-breaking oral plenary presentation
- ➤ACR-2316 showed confirmed CR in squamous NSCLC and PR in SCLC
- ➤ACR-2316 delivered over one year of clinical benefit in lung adenocarcinoma
- ➤ACR-7280 produced complete tumor regression in aggressive AML preclinical models
- ➤ACR-368 is advancing in a potentially registrational Phase 2 endometrial cancer trial
Expert Statements
Timothy A. Yap, MBBS, Ph.D., FRCP, The University of Texas MD Anderson Cancer Center
“Safety, dose optimization, and preliminary antitumor activity from a Phase 1 dose escalation study of ACR-2316, a novel WEE1/PKMYT1 inhibitor”
WATERTOWN, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced presentations at the upcoming the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place November 18-20, 2026, in Barcelona, Spain.
Following the presentations, copies will be available on the Acrivon website under “Posters and Presentations” or by using this LINK.
Get started
Create a free account to read the full story.